How AI Can Revolutionize Heart Failure Care
Clinical Advances, Challenges, and Future Perspectives
In this episode of Heart Failure Beat, Priya and Michael interview Dr. Partho Sengupta – cardiology artificial intelligence (AI) aficionado – who shares his expertise on the role of AI in transforming cardiovascular care, from diagnostics to personalized treatment. On Heart Failure Rounds, Michael discusses the latest research on nurse-led titration clinics and their significant impact on heart failure rehospitalizations and mortality. The episode wraps up with Priya’s review of the latest trials presented at the European Society of Cardiology (ESC), highlighting new therapies and breakthroughs in cardiac and kidney care on From Failure to Function. A must-listen for clinicians interested in cutting-edge heart failure management.
Listen below and subscribe: Apple Podcasts, Amazon Music, Spotify, Podcast Home
Hosts:
-
Michael Beasley, MD, Assistant Professor of Medicine at the Yale School of Medicine @MHBeasleyMD
-
Priya Umapathi, MD, Assistant Professor in the Division of Cardiology & Advanced Heart Failure and Heart Transplant Cardiologist at Johns Hopkins Hospital @priyaumapathi
Chapters and Guests:
-
1:51-11:56 Heart Failure Rounds
- Michael Beasley, MD, Assistant Professor of Medicine at the Yale School of Medicine
- Michael Beasley, MD, Assistant Professor of Medicine at the Yale School of Medicine
-
11:56-43:42 Featured Interview: How AI Can Revolutionize Heart Failure Care
-
Partho P. Sengupta, MD, DM, FACC, FASE, Henry Rutgers Professor of Cardiology at Rutgers Robert Wood Johnson Medical School
-
-
43:29-47:19 From Failure to Function
-
Priya Umapathi, MD, Assistant Professor in the Division of Cardiology & Advanced Heart Failure and Heart Transplant Cardiologist at Johns Hopkins Hospital
-
References
-
Driscoll, A. , Meagher, S. , Kennedy, R. & Currey, J. (2024). Effect of Intensive Nurse-Led Optimization of Heart Failure Medications in Patients With Heart Failure. The Journal of Cardiovascular Nursing, 39 (5), 417-426. doi: 10.1097/JCN.0000000000001068.
-
Marzinski, Sara DNP, RN, AGCNS-BC; Melrose, Diane MSN, RN, AGCNS-BC, CV-BC; Moynihan, Therese MSN, RN, AGCNS-BC, CHFN-K; Hlebichuk, Jeanne PhD, RN, NE-BC; Liao, Yunqi MS; Hook, Mary PhD, RN-BC. Knowing the Patient: Understanding Readmission Reasons in Complex Heart Failure. The Journal of Cardiovascular Nursing 39(5):p 438-448, 9/10 2024. | DOI: 10.1097/JCN.0000000000001061
- Duvalyan A, La Hoz RM, McGuire DK, Drazner MH. Sodium-Glucose Cotransporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure. J Card Fail. 2024 Apr 25:S1071-9164(24)00145-3. doi: 10.1016/j.cardfail.2024.04.009. Epub ahead of print. PMID: 38670430.
-
GREWAL, J. S., & SENGUPTA, P. P. (2024b). Pitfalls and opportunities for the growing role of AI in heart failure. Journal of Cardiac Failure, 30(6), 838–840. https://doi.org/10.1016/j.cardfail.2024.03.001
-
Saha, A. (2024, September 12). SEMAGLUTIDE effects on cardiovascular outcomes in people with overweight or obesity. American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/11/09/15/04/select
-
Healthcare, G. (2024, August 30). ESC 2024: Latest flow trial analysis highlights how ozempic can benefit CKD patients. Pharmaceutical Technology. https://www.pharmaceutical-technology.com/analyst-comment/esc-2024-latest-flow-trial-analysis-highlights-how-ozempic-can-benefit-ckd-patients/